Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma, a late-stage biopharmaceutical company, has signed a collaboration agreement with BurnsAdler Pharmaceuticals, a specialty pharmaceutical company based in North Carolina.
Subscribe to our email newsletter
Pursuant to the agreement, BurnsAdler will act as Dor’s distributor of a named patient access program (NPAP) for orBec to patients suffering from acute gastrointestinal graft-versus-host disease in all countries within Central America, South America and the Caribbean.
The NPAP is a compassionate use drug supply program under which medical practitioners can legally supply investigational drugs to their eligible patients. Under this program, investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the regional regulatory authorities.
BurnsAdler and Dor will share revenues generated by sales of orBec through the NPAP. Dor will manufacture and supply orBec to BurnsAdler, while BurnsAdler will be responsible for all distribution costs in the territory.
Bryan Somerville, president of BurnsAdler, said: “There is an acute need for a new drug to treat gastrointestinal graft-versus-host disease (GI GVHD) as a result of hematopoietic stem cell transplantation in Latin America.
“Given the impressive pharmacology orBec has shown as well as the fact that it is the first directed therapy for patients suffering from GI GVHD, we are glad to be able to make this innovative drug available to patients in Latin America.”